|Bid||133.93 x 800|
|Ask||134.27 x 800|
|Day's range||133.62 - 135.53|
|52-week range||117.64 - 189.00|
|Beta (5Y monthly)||0.94|
|PE ratio (TTM)||N/A|
|Earnings date||21 Feb 2022 - 25 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||201.05|
Belgium-based UCB is set to acquire Zogenix (ZGNX) for a total transaction value of $1.9 billion in cash. The transaction is likely to be completed by second-quarter 2022.
The average of price targets set by Wall Street analysts indicates a potential upside of 41.5% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Let's consider two such companies: Jazz Pharmaceuticals (NASDAQ: JAZZ) and Netflix (NASDAQ: NFLX). It's never good to be too reliant on a single product, and until recently Jazz Pharmaceuticals -- based in Dublin, Ireland -- relied heavily on Xyrem, a medicine that helps treat narcolepsy. The deal closed in May and cost Jazz $7.2 billion in cash and stock.